Detalhe da pesquisa
1.
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.
Brain
; 147(4): 1206-1215, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38085047
2.
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538060
3.
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
J Neurol Neurosurg Psychiatry
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38569872
4.
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Mult Scler
; 29(2): 221-235, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433775
5.
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Mult Scler
; 29(7): 875-883, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36851894
6.
Neuroimaging characteristics may aid in diagnosis, subtyping, and prognosis in autoimmune encephalitis.
Neurol Sci
; 44(4): 1327-1340, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36481972
7.
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 93(12): 1330-1337, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36261289
8.
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Mult Scler
; 28(6): 958-969, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34623947
9.
Psychometric deficits in autoimmune encephalitis: A retrospective study from the Australian Autoimmune Encephalitis Consortium.
Eur J Neurol
; 29(8): 2355-2366, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35460305
10.
Electroclinical biomarkers of autoimmune encephalitis.
Epilepsy Behav
; 128: 108571, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35101840
11.
Prevalence, risk factors, and prognosis of drug-resistant epilepsy in autoimmune encephalitis.
Epilepsy Behav
; 132: 108729, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35623203
12.
Characterising DSCATT: A case series of Australian patients with debilitating symptom complexes attributed to ticks.
Aust N Z J Psychiatry
; 56(8): 974-984, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34465249
13.
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Brain
; 143(9): 2742-2756, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32947619
14.
Early clinical markers of aggressive multiple sclerosis.
Brain
; 143(5): 1400-1413, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32386427
15.
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Mult Scler
; 26(14): 1866-1876, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31762387
16.
The safety and efficacy of dual biological therapy: Dupilumab and fremanezumab.
Australas J Dermatol
; 65(3): e63-e65, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38189530
17.
Incidence and prevalence of NMOSD in Australia and New Zealand.
J Neurol Neurosurg Psychiatry
; 88(8): 632-638, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28550069
18.
Motor neurone disease: progress and challenges.
Med J Aust
; 206(8): 357-362, 2017 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28446118
19.
Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
Mult Scler
; 22(7): 944-54, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26447066
20.
A new era in the treatment of multiple sclerosis.
Med J Aust
; 203(3): 139-41, 141e.1, 2015 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26224184